Genomic Health Jan 10, 2020 OncotypeDX Score May Give Valuable Info on Breast Cancer Locoregional Recurrence Nov 22, 2019 Racial Group Comparison Suggests More Research Needed on Prostate Cancer Recurrence Tests Premium Nov 20, 2019 Lower Cutoff Score for Oncotype DX Test May Be Needed for Male Breast Cancer Patients Sep 30, 2019 TAILORx High-Risk Group Analysis Adds to Oncotype DX Chemo-Prediction Data Jul 29, 2019 Exact Sciences to Acquire Genomic Health for $2.8B; Q2 Revenues Rise 94 Percent Jun 28, 2019 Competing Breast Cancer Assays Beat Genomic Health's Oncotype Dx in Canadian Cost Modeling Study Premium Jun 13, 2019 ASCO Data Pushes Boundaries for Genomic Testing in Localized Breast Cancer Premium May 31, 2019 One Year Post-TAILORx: Attitudes Shift and Questions Linger in Breast Cancer Recurrence Testing Premium May 7, 2019 Genomic Health Q1 Revenues Up 17 Percent Feb 22, 2019 Genomic Health Stresses Oncotype DX Value After Questions Raised by Recent Study Premium Dec 14, 2018 Black Women With Breast Cancer Fare Worse, TAILORx Analysis Confirms at SABCS Premium Oct 10, 2018 NCCN Update on Breast Cancer Genetic Testing Guidelines Marks Oncotype DX as 'Preferred' Test Aug 3, 2018 Post-TAILORx, Genomic Health Tightens Focus on International Expansion Premium Jun 8, 2018 At ASCO, Clinicians Discuss AR-V7 Test Comparison and Unresolved Questions About Utility Premium Jun 3, 2018 Fewer Breast Cancer Patients Benefit From Chemo, TAILORx Study With Oncotype DX Finds Mar 15, 2018 Genomic Health's Suspension of NGS Liquid Biopsy Program Highlights Market Challenges Premium Feb 7, 2018 UK's NICE Finalizing Updated Breast Cancer Test Guidance Following Stakeholder Comments Premium Jan 10, 2018 NICE Draft Guidance Reverses Endorsement of Oncotype Dx to Guide Chemotherapy Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer
